陇神戎发(300534) - 2024 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2024 was ¥254,914,282.74, a decrease of 13.97% compared to ¥296,323,324.22 in the same period last year[5] - Net profit attributable to shareholders was ¥22,141,028.38, an increase of 10.68% from ¥20,005,326.86 year-on-year[5] - Total operating revenue for Q1 2024 was CNY 254,914,282.74, a decrease of 14.0% compared to CNY 296,323,324.22 in Q1 2023[27] - Net profit for Q1 2024 reached CNY 30,802,639.46, an increase of 5.1% from CNY 29,294,351.56 in Q1 2023[28] - The total comprehensive income for the parent company was ¥22,141,028.38, up from ¥20,005,326.86 in the previous year, reflecting a growth of 10.7%[29] Cash Flow - The net cash flow from operating activities increased by 380.82% to ¥84,710,636.25, compared to a negative cash flow of -¥30,165,723.04 in the previous year[11] - The net cash flow from operating activities was ¥84,710,636.25, a significant improvement from a net outflow of ¥30,165,723.04 in the same period last year[32] - The cash inflow from operating activities totaled ¥273,094,245.34, down from ¥295,872,942.31 in the previous year, indicating a decrease of 7.7%[32] - The cash outflow from operating activities was ¥188,383,609.09, reduced from ¥326,038,665.35 in Q1 2023, showing a decrease of 42.3%[32] - The net cash flow from investing activities was -¥18,389,528.51, slightly worse than -¥16,994,742.18 in the previous year[32] - The net cash flow from financing activities was -¥27,905,177.64, an improvement from -¥45,165,588.34 in Q1 2023[33] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,430,015,994.51, reflecting a growth of 6.98% from ¥1,336,651,461.91 at the end of the previous year[5] - Total assets increased to CNY 1,430,015,994.51 from CNY 1,336,651,461.91, representing a growth of 7.0%[25] - Total liabilities rose to CNY 687,702,796.84, compared to CNY 625,140,903.70, marking an increase of 10.0%[25] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 31,929[13] - The largest shareholder, Gansu Pharmaceutical Investment Group Co., Ltd., holds a 29.93% stake in the company[13] - The company has no shareholders participating in margin financing and securities lending business[14] - The company reported a total of 1,153,742 shares under lock-up, with 182,475 shares released during the period[16] - The company has not disclosed any related party relationships among the top shareholders[14] Corporate Developments - The company completed the transfer of 7.11% equity (21,575,777 shares) from Gansu Biological Industry Venture Capital Fund to Gansu Xinglong Capital Management Co., Ltd. on December 29, 2023[17] - The company has been re-certified as a high-tech enterprise, with the certificate number GR202362000602, issued on December 12, 2023[19] - The company received approval for the re-registration of tannic acid berberine as a chemical raw material drug from the Gansu Provincial Drug Administration[20] - The company’s subsidiary, Puan Pharmaceutical, obtained a food production license from the Wuwei Market Supervision Administration[20] - The company decided to terminate the application for issuing shares to specific objects and withdrew the application due to changes in the financing environment and completion of some investment projects[21] - The company held its first temporary shareholders' meeting on January 3, 2024, to elect the fifth board of directors and supervisory board[18] - The company’s fifth board of directors and supervisory board have been successfully re-elected and new senior management appointed[18] Research and Development - Research and development expenses decreased by 30.31% year-on-year, indicating a reduction in project-related payments[10] - The company reported a decrease in research and development expenses to CNY 3,984,485.86 from CNY 5,717,764.87, a reduction of 30.4%[28] Earnings Per Share - The company's basic earnings per share rose to ¥0.0730, up 10.77% from ¥0.0659 in the same quarter last year[5] - The basic and diluted earnings per share for Q1 2024 were both ¥0.0730, compared to ¥0.0659 in Q1 2023, representing an increase of 16.9%[29] Financial Expenses - Financial expenses increased by 62.77% compared to the previous year, primarily due to reduced interest income and increased interest expenses on loans[10]